We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Ixico Plc | LSE:IXI | London | Ordinary Share | GB00BFXR4C20 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.125 | -1.43% | 8.625 | 8.50 | 8.75 | 8.75 | 8.625 | 8.75 | 6,800 | 16:18:38 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMIXI
RNS Number : 0775U
IXICO plc
19 October 2017
19 October 2017
IXICO plc
("IXICO" or the "Company")
Pre-Close Trading Update
Double-digit revenue growth
Three new contracts signed in September, including first wearables contract
IXICO plc (AIM: IXI), the digital technologies company serving neuroscience, today provides the following pre-close trading update ahead of its preliminary results for the year ended 30 September 2017.
The Company is pleased to report revenue for the year of GBP3.7 million (2016: GBP3.1 million). The GBP0.6 million increase, or c.20% growth over the prior year, reflects traction in the Company's commercially led organic growth strategy focused on the global biopharma market. As a result the Company expects to be ahead of expectations for EBITDA and operating losses for the current financial year.
This strong performance highlights the increasing adoption by global biopharma of IXICO's technology enabled specialty services for clinical trials in a broad range of neurodegenerative diseases such as Alzheimer's Disease, Parkinson's Disease, PSP and Huntington's Disease. New multi-year contracts signed in the year include an Alzheimer's Disease clinical trial announced in July and two new contracts in Huntington's Disease announced in September. These new agreements, combined with existing projects, further strengthen the Company's order book and provide a foundation of future revenue over the multi-year term of each clinical trial.
Revenue in the year also reflected an expansion and extension of the commercial collaboration pilot of the Assessa(R) PML platform with Biogen to include pharmacovigilance reporting (monitoring the effects of medical drugs in order to identify and evaluate previously unreported adverse reactions). Work on this pilot will continue in the financial year ahead.
Reflecting previous development investments in innovation, the Company announced on 29 September that it had signed its first commercial agreement to deploy new wearable and advanced algorithm analytics in a Phase II clinical trial. This places IXICO at the forefront of biopharma's adoption of digital biosensor technologies in clinical trials and represents an exciting new area of growth.
Other income of GBP0.6 million (2016: GBP0.7 million) reflected lower grant income of GBP0.5 million (2016: GBP0.6 million) as resources were focused on customer projects. Total income increased to GBP4.3 million (2016: GBP3.8 million).
Net cash at 30 September 2017 was GBP2.4 million (2016: GBP3.1 million) which was a modest reduction from the net cash figure of GBP2.8 million at 31 March 2017. Second half cash flows included grant reimbursement and R&D tax credits.
The Company anticipates that its preliminary results to 30 September 2017 will be announced in December 2017.
For further information please contact:
IXICO plc Giulio Cerroni, Chief Executive Tel: +44 20 Officer 3763 7499 Susan Lowther, Chief Financial Officer Shore Capital (Nomad and Broker) Tel: +44 20 Edward Mansfield/Anita Ghanekar 7408 4090 FTI Consulting Limited (Investor Tel: +44 20 Relations) 3727 1000 Simon Conway/Mo Noonan
About IXICO
IXICO is the digital technologies company serving neuroscience. Our mission is to transform the pursuit of improving brain health through the application of digital technologies to neuroscience. IXICO's specialist data analytics services are used by the global pharmaceutical industry to select participants for clinical trials, assess the safety and efficacy of new drugs in development and in post marketing surveillance. Our neurological disease focus includes Alzheimer's disease, Huntington's disease, Multiple Sclerosis, Parkinson's disease and our integrated digital platform encompasses the entire drug development lifecycle. It is a scalable and secure infrastructure for the capture and analysis of regulatory compliant clinical data to enable sponsors to make rapid, better informed decisions. IXICO is also collaborating with partners to develop new companion digital health products targeted at improving patient outcomes.
More information is available on www.IXICO.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
TSTGCBDGXBBBGRC
(END) Dow Jones Newswires
October 19, 2017 05:14 ET (09:14 GMT)
1 Year Ixico Chart |
1 Month Ixico Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions